A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.
10.1007/s11684-020-0808-3
- Author:
Houli ZHAO
1
;
Yiyun WANG
1
;
Elaine Tan Su YIN
1
;
Kui ZHAO
2
;
Yongxian HU
3
;
He HUANG
4
Author Information
1. Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
2. PET-CT Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China.
3. Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China. huyongxian2000@aliyun.com.
4. Bone Marrow Transplantation Center, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 310000, China. huanghe@zju.edu.cn.
- Publication Type:Review
- Keywords:
chimeric antigen receptor T (CAR-T) cell;
cytokine release syndrome (CRS);
immune effector cell-associated neurotoxicity syndrome (ICANS);
lymphoma
- MeSH:
Cell- and Tissue-Based Therapy;
Humans;
Immunotherapy, Adoptive;
Lymphoma/therapy*;
Receptors, Antigen, T-Cell;
Receptors, Chimeric Antigen
- From:
Frontiers of Medicine
2020;14(6):711-725
- CountryChina
- Language:English
-
Abstract:
The combination of the immunotherapy (i.e., the use of monoclonal antibodies) and the conventional chemotherapy increases the long-term survival of patients with lymphoma. However, for patients with relapsed or treatment-resistant lymphoma, a novel treatment approach is urgently needed. Chimeric antigen receptor T (CAR-T) cells were introduced as a treatment for these patients. Based on recent clinical data, approximately 50% of patients with relapsed or refractory B-cell lymphoma achieved complete remission after receiving the CD19 CAR-T cell therapy. Moreover, clinical data revealed that some patients remained in remission for more than two years after the CAR-T cell therapy. Other than the CD19-targeted CAR-T, the novel target antigens, such as CD20, CD22, CD30, and CD37, which were greatly expressed on lymphoma cells, were studied under preclinical and clinical evaluations for use in the treatment of lymphoma. Nonetheless, the CAR-T therapy was usually associated with potentially lethal adverse effects, such as the cytokine release syndrome and the neurotoxicity. Therefore, optimizing the structure of CAR, creating new drugs, and combining CAR-T cell therapy with stem cell transplantation are potential solutions to increase the effectiveness of treatment and reduce the toxicity in patients with lymphoma after the CAR-T cell therapy.
